The method of producing a lipid composition comprises an extraction treatment step to extract a lipid comprised in a hydrated raw material by using an extraction solvent comprising a polar solvent and a nonpolar solvent, and a separation treatment step to separate an extract solution obtained in the extraction treatment step into a polar solvent phase comprising a first lipid fraction and a nonpolar solvent phase comprising a second lipid fraction.

The subject invention provides materials and methods for producing and purifying sophorolipids (SLP). More specifically, the subject invention provides materials and methods for the purification of both hydrophobic and hydrophilic SLP molecules to a purity of, for example, at least 80% by weight, preferably at least 95% by weight, without using solvents or centrifugation. Advantageously, the subject invention is suitable for industrial scale production of purified SLP for use in, for example, cleaning products and detergents, and uses safe and environmentally-friendly materials and processes.

The subject invention provides materials and methods for producing and purifying sophorolipids (SLP). More specifically, the subject invention provides materials and methods for the purification of both hydrophobic and hydrophilic SLP molecules to a purity of, for example, at least 80% by weight, preferably at least 95% by weight, without using solvents or centrifugation. Advantageously, the subject invention is suitable for industrial scale production of purified SLP for use in, for example, cleaning products and detergents, and uses safe and environmentally-friendly materials and processes.

A method for manufacturing a functional material that contains plasmalogen, the method including treating an animal tissue containing plasmalogen with protease, and extracting the animal tissue treated with protease with an extraction liquid containing ethanol.

The present disclosure discloses application of a microbiota-derived plasmalogens to treatment of colon cancer, and belongs to the technical field of biomedicine and microorganisms. The microbiota-derived plasmalogens provided in the present disclosure is extracted from an anaerobic microorganism including any one or more of Lactobacillaceae, Bifidobacterium, Clostridium butyricum, and Peptostreptococcus Kluyver and van Niel after fermentation. The microbiota-derived plasmalogens can reduce expressions of colon cancer-associated cytokines at the molecular level, inhibit the proliferation of colon cancer cells, and reduce the number and size of colon adenomas in patients with colon cancer. The microbiota-derived plasmalogens can be used as an effective nutrition strategy for preventing and treating the colon cancer, and a theoretical support is provided for efficient utilization of the enteric microbiota-derived plasmalogens.

The invention provides a process of incorporation of omega-3 fatty acids such as EPA/DHA into polar lipid molecules present in lecithin, which consists of: (a) an enzymatic exchange reaction between the fatty acids present in the polar lipids of lecithin and the omega-3 fatty acids present in concentrated fish oil, to obtain an oil with a high content of polar lipids and omega-3 fatty acids and (b) a stage of concentration of the polar lipid content of the oil obtained in stage a, by supercritical fractionation or molecular distillation.

Methods for hydrolyzing solid ungranulated lysophosphatidylcholine with phospholipase A.sub.2 are provided. Also disclosed are methods for making a lipid matrix of lysophosphatidylcholine, monoglyceride and fatty acid, and lipid matrices of particular structure.

The present invention concerns phospholipid compositions having a relatively high concentration of compounds of the following structure (I): wherein at least one of R.sup.1 and R.sup.2 is palmitoleoyl, myristoleoyl or lauroleoyl and methods for their preparation. The present invention also concerns the use of these phospholipid compositions to treat a variety of disorders by administering the composition to a patient in need thereof. ##STR00001##

The subject invention provides methods for producing phospholipids using yeasts not previously known to produce high concentrations of such phospholipids. In particular, Wickerhamomyces anomalus is cultivated in a specially-tailored nutrient medium and under cultivation conditions such that the yeast unnaturally produces high concentrations of phospholipids that resemble human cardiolipin and/or precursors thereof in structure and/or function. Yeast culture compositions are also provided, comprising yeast cells, growth medium, and high concentrations of phospholipids.

A method for manufacturing a functional material that contains plasmalogen, the method including treating an animal tissue containing plasmalogen with protease, and extracting the animal tissue treated with protease with an extraction liquid containing ethanol.